Showing results (281-290 of 291) with videos related to
Sort By:
Pageof 30
Leukemia|May 4, 2016
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic featuresV I Gaidzik, V Teleanu, E Papaemmanuil, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survivalMax S Topp, Peter Kufer, Nicola Gökbuget, et al.Blood|September 27, 2019
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study GroupFrank G Rücker, Mridul Agrawal, Andrea Corbacioglu, et al.Annals of the American Thoracic Society|August 12, 2021
Comparing Smoking Cessation Interventions among Underserved Patients Referred for Lung Cancer Screening: A Pragmatic Trial ProtocolRachel Kohn, Anil Vachani, Dylan Small, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2019
Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III StudyRichard F Schlenk, Peter Paschka, Julia Krzykalla, et al.Blood Cancer Journal|May 27, 2017
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemiaS Jaramillo, A Benner, J Krauter, et al.Annals of Hematology|November 2, 2017
Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)Gabriele Nagel, D Weber, E Fromm, et al.Leukemia|May 4, 2018
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trialPeter Paschka, Richard F Schlenk, Daniela Weber, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemiaSanne Lugthart, Stefan Gröschel, H Berna Beverloo, et al.Blood|December 28, 2020
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trialSilke Kapp-Schwoerer, Daniela Weber, Andrea Corbacioglu, et al.Pageof 30